Meanwhile, Lilly has reported positive Phase 3 topline results for its oral GLP-1 candidate Orforglipron in obesity, underscoring that the next battleground is likely to be pill-based scale-up, access, and brand-led persistence rather than efficacy alone
These findings suggest that GLP-1RAs could represent a promising pharmacological approach for treating asthma in obese patients [47]
Managing type 2 diabetes or addressing significant weight loss with medications like Semaglutide (marketed as Ozempic) can be life-changing
To date, most clinical studies have been of short duration (412 weeks), and long-term safety data in neurodegenerative populations are lacking (Satoh et al., 2009)
3eg and Supplementary Fig
According to the cited figure 3[14], the increase of NADPH concentration from 2,5 mM [1] up to 10 mM also increases the velocity of GR and the GSH reserve levels, that are increased from 10 mM up to 100 mM, in such a way to always saturate GP activity